{"entity":{"id":"nct02802423","kind":"trial","name":"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.","aka":[],"tldr":"A phase 1/2 trial in triple-negative breast cancer, run by BioLite, Inc., not yet recruiting.","summary":"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. is a phase 1/2, interventional study registered as NCT02802423 by BioLite, Inc., with a registry enrolment figure of 44 participants, started 2027-01-01 and due to reach its primary completion in 2028-04-30. Interventions recorded: BLEX 404 Oral Liquid. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Patients with histologically or pathologically diagnosed with advanced/metastatic triple negative (ER-, PR-, and HER2-negative) breast cancer\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02802423","url":"https://clinicaltrials.gov/study/NCT02802423"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02802423","phase":"1/2","setting":"A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase IIA Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid With Adjuvant Chemotherapy in Patients With Triple Negative Breast Cancer (TNBC) After Surgery","sponsor":"BioLite, Inc.","participation":[{"nct":"NCT02802423","source":"https://clinicaltrials.gov/study/NCT02802423","fetchedAt":"2026-10-07T16:52:51.872Z","studySha256":"a236188eb7a80e832d3f6fb5eb6c4835fbe1533e24395716ad69f0c679cd2a70","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-04-13","leadSponsor":"BioLite, Inc.","collaboratorCount":0,"minimumAge":"20 Years","maximumAge":"70 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":44,"enrolmentType":"ESTIMATED","siteCount":0,"recruitingSiteCount":0}],"started":"2027-01-01","startedType":"estimated","enrolled":44,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02802423/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}